Dobutamine Hydrochloride In Dextrose 5% In Plastic Container — Competitive Intelligence Brief

Dobutamine Hydrochloride In Dextrose 5% In Plastic Container (Dobutamine Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inotropic agent. Area: Cardiovascular.

marketed Inotropic agent Beta-receptors of the heart Cardiovascular Small molecule

Target snapshot

Dobutamine Hydrochloride In Dextrose 5% In Plastic Container (Dobutamine Hydrochloride) — Pfizer Inc.. Direct-acting inotropic agent stimulating cardiac beta-receptors with mild chronotropic and vasodilative effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dobutamine Hydrochloride In Dextrose 5% In Plastic Container TARGET	Dobutamine Hydrochloride	Pfizer Inc.	marketed	Inotropic agent	Beta-receptors of the heart	1978-01-01
Levosimendan Injection	Levosimendan Injection	Peking University Third Hospital	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
Levosimontane injection	Levosimontane injection	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
low-dose dopamine + low-dose furosemide	low-dose dopamine + low-dose furosemide	Larissa University Hospital	marketed	Combination diuretic and inotropic agent	Dopamine-1 (DA1) receptor; Na-K-2Cl cotransporter
Milrinone Lactate	Milrinone Lactate	Pfizer Inc.	marketed	Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator	Phosphodiesterase-3 (PDE-3) enzyme
inotropes therapy	inotropes therapy	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Inotropic agent
epinephrine and levosimendan	epinephrine and levosimendan	Federal University of Juiz de Fora	marketed	Inotropic agent combination	Adrenergic receptors (alpha-1, beta-1) and cardiac troponin C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inotropic agent class)

1. Pfizer Inc. · 1 drug in this class
2. Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class